Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy

Cardiovascular Drugs and Therapy

Volumn 21, Issue 5, 2007, Pages 367-374

  Chen, Xing ^a   Chen, Yongli ^b   Bi, Yanyong ^a   Fu, Naikuan ^b   Shan, Chunyan ^a   Wang, Sili ^c   Aslam, Shahid ^a   Wang, Peixian ^a   Xu, Jing ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN CHEST HOSPITAL   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Cardiomyopathy; Doxorubicin; Erythropoietin

Indexed keywords

ALPHA ACTININ; DOXORUBICIN; ERYTHROPOIETIN; PROTEIN BAX; PROTEIN BCL 2; TROPONIN T;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART PROTECTION; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT;

ACTININ; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOXORUBICIN; ECHOCARDIOGRAPHY; ERYTHROPOIETIN; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, WISTAR; TROPONIN T;

EID: 35349001269     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6052-0     Document Type: Article

References (40)

1. Li K, Sung RYZ, Huang WZ, et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006;113:2211-20.
2. Khan M, Varadharaj S, Shobha JC, et al. C-Phycocyanin Ameliorates Doxorubicin-Induced Oxidative Stress and Apoptosis in Adult Rat Cardiomyocytes. J Cardiovasc Pharmacol 2006;47:9-20.
3. Kotamraju S, Konorev EA, Joseph J, et al. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000;275:33585-92.
4. Kluza J, Marchetti P, Gallego M-A, et al. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 2004;23:7018-30.
5. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vitro causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res 2002;62:4592-8.
6. Kluza J, Marchetti P, Gallego MA, et al. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 2004;23:7018-30.
7. Wang S, Konorev EA, Kotamraju S, et al. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. J Biol Chem 2004;279:25535-43.
8. Simpson C, Herr H, Courville KA. Concurrent therapies that protect against doxorubicin-induced cardiomyopathy. Clin J Oncol Nurs 2004;8:497-501.
9. Iarussi D, Indol P, Casale F, et al. Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chem 2001;8:1649-60.
10. van der Meer P, Voors AA, Lipsic E, et al. Erythropoietin in cardiovascular diseases. Eur Heart J 2004;25:285-91.
11. Li L, Takemura G, Li Y, et al. Preventive effect of erythropoietin of cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006;113:535-43.
12. Hamed S, Barshack I, Luboshits G, et al. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 2006;27:1876-83.
13. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003:112:999-1007.
14. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin Just Before Reperfusion Reduces Both Lethal Arrhythmias and Infarct Size via the Phosphatidylinositol-3 Kinase-Dependent Pathway in Canine Hearts. Cardiovasc Drug Ther 2005;19:33-40.
15. Chlopcikova S, Psotova J, Miketova P. Neonatal rat cardiomyocytes: a model for the study of morphological, biochemical and electrophysiological characteristics of the heart. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2001;145:49-55.
16. Fisher PW, Salloum F, Das A, et al. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005;111:1601-10.
17. Chatterjee S, Stewart AS, Bish LT, et al. Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation 2002;106:I-212-7.
18. Hou XW, Son J, Wang Y, et al. Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drug Ther 2006;20:85-91.
19. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-6.
20. Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004;63:208-16.
21. Nomoto T, Nishina T, Miwa S, et al. Angiotensin-converting enzyme inhibitor helps prevent late remodeling after left ventricular aneurysm repair in rats. Circulation 2002;106:I-115-9.
22. Chatterjee S, Stewart AS, Bish LT, et al. Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation 2002;106:I-212-7.
23. Green PS, Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta 2002;1588:94-101.
24. Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004;37:837-46.
25. Teraoka K, Hirano M, Yamaguchi K, Yamashina A. Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail 2000;2:373-8.
26. Li T, Singal PK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 2000;102:2105-10.
27. Nakamura T, Ueda Y, Guan Y, et al. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 2000;102:572-8.
28. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41.
29. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-9.
30. Cook SA, Poole-Wilson PA. Cardiac myocyte apoptosis. Eur Heart J 1999;20:1619-29.
31. Kajstura J, Leri A, Finato N, et a1. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci USA 1998;95:8801-5.
32. Beltrami AP, Urbanek K, Kajstura J et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001;344:1750-7.
33. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-12.
34. Sabbah HN. Apoptotic cell death in heart failure. Cardiovasc Res 2000;45:704-12.
35. Nicholson DW, Thornberry NA. Apoptosis. Life and death decisions. Science 2003;299:214-5.
36. Oltvai ZN, Millimau CL, Karsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-704.
37. Wang N, Minatoguchi S, Chen X, et al. Antidiabetic drug miglitol inhibits myocardial apoptosis involving decreased hydroxyl radical production and Bax expression in an ischaemia/reperfusion rabbit heart. Br J Pharmacol 2004;142:983-90.
38. Li Y, Cohen R. Caspase inhibitors and myocardial apoptosis. Int Anesthesiol Clin 2005;43:77-89.
39. Golstein P. Controlling cell death. Science 1997;275:1081-2.
40. Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol 2001;11:526-34.